KEYNOTE trials show pembrolizumab benefited patients with advanced small cell lung cancer

11:14 EDT 11 Apr 2019 | ecancermedicalscience

Prof Chung Hyun Cheol gives a press conference at AACR 2019 on the data from two separate KEYNOTE trials that showed anti-PD-1 monoclonal antibody pembrolizumab was a benefit to patients with advanced small cell lung cancer.

More From BioPortfolio on "KEYNOTE trials show pembrolizumab benefited patients with advanced small cell lung cancer"